ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO513

The Association between Plasma PCSK9 Concentrations and CKD

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 304 CKD: Epidemiology, Outcomes - Non-Cardiovascular


  • Kim, Ha yeon, Chonnam National University Medical School, Gwangju, Korea (the Republic of)
  • Bae, Eun Hui, Chonnam National University Hospital, Gwangju, Korea (the Republic of)
  • Ma, Seong Kwon, Chonnam National University Medical School, Gwangju, Korea (the Republic of)
  • Kim, Soo Wan, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Dyslipidemia commonly appear in patients with chronic kidney disease (CKD) presenting with unique characteristics. The proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of the low-density lipoprotein receptor and plasma cholesterol concentrations. We studied the association of circulating PCSK9 concentrations with both estimated glomerular filtration rate (eGFR) and serum lipid parameters in patients at different stage of CKD.


We evaluated plasma PCSK9 concentrations measured by ELISA in 90 non-dialysis patients at different stage of CKD. We assessed their lipid profile including total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), urine albumin creatinine ratio (UACR), C-reactive protein (CRP), use of statins or fibrate, presence of hypertension, diabetes, chronic kidney disease, smoking, malignancy and coronary artery disease.


The mean plasma level of PCSK9 was 309.7 ± 74.6 ng/ml in the 90 patients. Plasma PCSK9 concentration has a positive correlation with UACR (r=0.261, P =0.029) and triglyceride (r = 0.316, P = 0.007), but not with total cholesterol (P =0.142) , eGFR (P =0.058), HDL-C (P =0.319), LDL-C (P =0.101), ApoA1 (P =0.380), ApoB (P =0.805), ApoA1/B (P =0.893) and CRP (P =0.457). In the patients with UACR ≥ 1g/gCr, plasma PCSK9 levels increase compared to patient with UACR <1g/gCr, (361.9 ± 60.3 ng/ml vs. 299.3 ± 73.2 ng/ml, P =0.008). Plasma PCSK9 level was independently associated with existence of diabetes and statin/fibrate medication. The concentrations of PCSK9 according to CKD stages were 273.0 ± 56.5 ng/ml in the CKD stage 1, 317.5 ± 98.4 ng/ml in the CKD stage 2, 306.6 ± 68.7 ng/ml in the CKD stage 3, 333.1 ± 85.6 ng/ml in the CKD stage 4, and 306.0 ± 64.3 ng/ml in the CKD stage 5 without dialysis, respectively. The levels of PCSK9 in patients with CKD stage 1 were lower than those of other stages (P = 0.032).


Plasma PCSK9 concentrations are related to proteinuria, but not associated to eGFR in patient with CKD.